Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Phase 1
Terminated
- Conditions
- Relapsed/Recurrent GBM (Phase 2)Solid Tumors (Phase 1)
- Interventions
- Drug: USL311Drug: Lomustine
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Proximagen, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02765165
- Locations
- 🇺🇸
University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸University of Texas/MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
© Copyright 2025. All Rights Reserved by MedPath